Agammaglobulinemia (Hypogammaglobulinemia)

01/01/2019 - "There was a significant reduction in mortality (OR 0.34 [0.17-0.69]; 4 studies, n = 455) in heart transplant with hypogammaglobulinemia receiving IVIG vs no IVIG. "
07/11/2023 - "Hypogammaglobulinemia was reported in 4 studies, with a prevalence of 75.3% (n = 256/340) of the patients, with IV immunoglobulin used in 48% (n = 123/256) of them. "
01/01/2019 - "Mortality in lung transplant recipients with hypogammaglobulinemia receiving IVIG was comparable to those of no hypogammaglobulinemia (OR 1.05 [0.49, 2.26]; 2 studies, n = 887). "
05/01/2006 - "Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia."
06/01/2023 - "The highest indications for IVIG among all patients were hypogammaglobulinemia and other deficiency states in 127 patients (26.3%). "

02/01/2022 - "A statistically significant reduction in serum IgG value was observed after 12 months from the start of treatment, where only one out of 26 (3.8%) patients developed hypogammaglobulinemia with IgG less than 6 g/L but none developed hypogammaglobulinemia of less than 5 g/L. "
07/01/2005 - "Serum IgG levels between 300-500 mg/dl are sufficient for effective treatment of hypogammaglobulinemias. "
01/01/2012 - "Seven of the eight patients identified in our search demonstrated simultaneous improvement in AD and serum IgG levels within 2 years of initial presentation, suggesting a diagnosis of transient hypogammaglobulinemia. "
01/01/2019 - "This study has also shown most asymptomatic patients with moderate hypogammaglobulinemia (IgG 3.0-6.9 g/l) have been in good health for a mean observation period of 96 months. "
09/01/1990 - "Few pigs had hypogammaglobulinemia, less than 3% of the study population had serum IgG concentrations less than 1 g/dl. "

12/01/2020 - "Further studies are needed to elucidate the etiology of hypogammaglobulinemia and to establish criteria for immunoglobulin replacement in these patients."
11/01/2009 - "The aim of this study was to review the clinical and laboratory records of patients with unclassified hypogammaglobulinemia and to evaluate whether these children experience changes in serum immunoglobulin concentrations during long-term followup and have an exact diagnosis in natural course of disease. "
09/01/1965 - "Immunoglobulin studies in six kindreds of patients with adult hypogammaglobulinemia."
11/06/2023 - "Persistent hypogammaglobulinemia and immunoglobulin substitution dependence has been observed in several patients after RTX treatment despite the normalization of total B cell numbers. "
11/01/2023 - "Hypogammaglobulinemia is characterized by reduced serum immunoglobulin levels. "

09/01/2020 - "Rituximab is effective for PTLD; however, rituximab can produce adverse effects, including hypogammaglobulinemia. "
07/01/2023 - "These results may help to inform clinical decision when considering a treatment by rituximab in immunosuppressed AID patients with hypogammaglobulinemia."
01/01/2023 - "This study aims to assess factors associated with hypogammaglobulinemia in AAV patients treated with rituximab. "
11/06/2023 - "Persistent Hypogammaglobulinemia after Receiving Rituximab Post-HSCT Is Not Caused by an Intrinsic B Cell Defect."
04/19/2023 - "from 262 patients with autoimmune rheumatological disease who received treatment with Rituximab; We identified 8 patients with persistent hypogammaglobulinemia (6 women and 2 men), this is a prevalence of 3.1%. "

08/01/1964 - "HYPOGAMMAGLOBULINEMIA; IODINATED GAMMA GLOBULIN STUDIES."
12/01/2023 - "A high-risk FLIPI score was identified as a risk factor for hypogammaglobulinemia (ods ratio: 4.51; 95% confidence interval: 1.29-15.68; p < 0.001) and basal gamma globulin level as a protective factor (odds ratio: 0.92; 95% confidence interval: 0.988-0.996; p  =  0.018). "
01/01/2021 - "Some children will also have hypogammaglobulinemia and impaired antibody responses requiring supplemental gamma globulin. "
11/01/2002 - "He was diagnosed with agammaglobulinemia at the age of 6 years and had been receiving gamma-globulin supplementation since then. "
11/11/1995 - "[The safety of treatment with intravenous gamma-globulin in patients with primary hypogammaglobulinemias]."

12/01/1998 - "Anemia, lymphopenia, hypogammaglobulinemia, profound anti-F1 cytotoxicity, and the loss of cytotoxic potential against third party alloantigen is seen in acute lethal GVH disease. "
08/01/1995 - "Acute lethal GVH disease is characterized by anemia, lymphopenia, hypogammaglobulinemia, profound anti-F1 cytotoxicity, and the loss of cytotoxic potential against third-party alloantigen. "
10/01/1993 - "Acute lethal GVH disease is characterized by anemia, lymphopenia, hypogammaglobulinemia, profound anti-F1 cytotoxicity, and the loss of cytotoxic potential against third-party alloantigen. "

03/01/2020 - "However, the incidence and clinical implications of low immunoglobulin M (IgM) or hypogammaglobulinemia have not been studied in detail. "
01/01/2020 - "He was found to have high inflammatory markers, hypogammaglobulinemia, monoclonal IgM - kappa light chain in serum and increased radiotracer uptake in the whole bone scintigraphy. "
01/01/2018 - "Serum was collected from a patient with agammaglobulinemia and supplemented with purified serum IgM to normal levels. "
01/01/2016 - "Los anticuerpos se reconocieron como parte de la respuesta inmunitaria humoral desde hace más de un siglo, tiempo después de su descubrimiento se reconoció la primera inmunodeficiencia primaria de anticuerpos: la agammaglobulinemia, seguida por la inmunodeficiencia común variable y el síndrome de hiper-IgM. "
11/01/2014 - "Hypogammaglobulinemia was detected in one patient and decreased concentrations of immunoglobulin M (IgM) in two other patients. "

01/01/2022 - "Although treatment with anti-CD20 monoclonal antibodies (mAb) has improved outcomes in B-cell malignancies, it's associated with increased risk of hypogammaglobulinemia (HG). "
02/01/2018 - "Clinicians dealing with monoclonal antibodies against cancer therapy, especially RTX, should be aware of the increasing risks for symptomatic induced hypogammaglobulinemia and respiratory infections."
02/01/2003 - "Delayed diagnosis and anti-CD20 monoclonal antibodies therapy (associated with hypogammaglobulinemia) possibly played a major role in the severity of CD pseudomembranous colitis and in the occurrence of an inflammatory pseudotumor."
12/01/2021 - "Rituximab is a monoclonal antibody that targets CD20 B cells, and its use might result in persistent hypogammaglobulinemia. "
01/01/2016 - "The Anti-CD20 monoclonal antibody Rituximab suppresses B-lymphocytes and may induce hypogammaglobulinemia in treated patients. "

10/01/2014 - "We retrospectively analyzed 189 ITP patients receiving RTX in 3 referral centers in France and conducted a systematic review of 32 studies (results published 2001-2014) reporting the use of RTX for ITP, particularly searching for symptomatic secondary hypogammaglobulinemia. "
10/01/2014 - "Finally, we found 4 case reports of ITP and symptomatic hypogammaglobulinemia possibly related to RTX according to the authors. "
10/01/2014 - "We also searched for case reports of hypogammaglobulinemia after RTX initiation for ITP. "
04/01/2005 - "A retrospective review of 46 courses of IGIV therapy showed that the therapy was most often used for hematologic, neurologic, and immunologic indications, and the most common diagnoses for which it was used were hypogammaglobulinemia, ITP, and CIDP. "
01/01/2022 - "We consider many possibilities beyond primary ITP e.g., hypogammaglobulinemia, chronic infection, and anemia, and how to approach their diagnosis and management. "

01/01/2022 - "At the last relapse, she was unable to walk and developed immunosuppressant-induced hypogammaglobulinemia. "
09/01/2000 - "The finding of unexpected hypogammaglobulinemia and concomitant infectious complications in six heart transplant recipients highlights a possible complication in a subset of patients receiving newer immunosuppressive agents. "
08/01/1985 - "Case 1, a patient with pure red blood cell aplasia and hypogammaglobulinemia, was treated after surgery with immunosuppressive agents. "
03/13/1999 - "Age, sex, hematological malignancy and its treatment, existence of neutropenia and hypogammaglobulinemia, administration of immunosuppressive agents, type (hospital or community-acquired) and localization of pneumonia, presence of respiratory failure and treatment response were reported. "
05/01/2016 - "Although rituximab therapy is effective in the treatment of many systemic autoimmune diseases and has an acceptable safety profile, treating physicians need to keep in mind that pre-existing hypogammaglobulinemia and likely also use of additional immunosuppressive agents can increase the risk of prolonged hypogammaglobulinemia and infection. "

01/01/2019 - "While RTX is an effective treatment for PTLD, hypogammaglobulinemia can persist for up to 2 years following RTX therapy, which may be associated with the higher cumulative rates of CPBI observed in RTX-treated patients."
09/01/2003 - "Patients with profound hypogammaglobulinemia who receive VAD as first line treatment are at a major risk of BI up to the completion of the fourth month of therapy. "
01/01/2022 - "Finally, we identify key areas for future study to mitigate and treat hypogammaglobulinemia resulting from this transformative therapy."
07/01/2010 - "Sixty-five patients with primary hypogammaglobulinemia on stable intravenous replacement therapy were included in a monocentric longitudinal trial. "
12/15/1980 - "[Case of hypogammaglobulinemia: clinical and immunological study, and possibilities of therapy]."

10/01/2007 - "At the study institution, hypogammaglobulinemia was found most often as a secondary immune deficiency due to chemotherapy or from complex cardiac anomalies. "
04/02/2022 - "Before chemotherapy, 109 cases (48.9%) were combined with hypogammaglobulinemia. "
11/01/2015 - "In most cases viral particles on electron microscopy are reported and the patients usually have a history of chemotherapy and hypogammaglobulinemia. "
06/01/2011 - " is concluded that hypogammaglobulinemia is a common complication in chemotherapy using RTX combined with CHOP, the decreased level of Ig is recovered to normal level about 1 year after stop of treatment, the decrease of Ig in some cases can last even for over 2 years."
04/01/2002 - "Patient characteristics included: median age 67 years (range, 40-83), median 3 chemotherapy treatments (range, 1-8), and hypogammaglobulinemia in 73% of patients. "

05/01/2013 - "The aim of this study is to describe the phenomenon of hypogammaglobulinemia (HGG) in the immediate post-transplantation period among children undergoing LTx. "
03/22/1957 - "Transplantation studies in patients with agammaglobulinemia."
08/01/2017 - "A national survey of screening and management of hypogammaglobulinemia in Canadian transplantation centers."
03/01/2016 - "Severe hypogammaglobulinemia (HGG) (IgG <400 mg/dL) following intestinal transplantation is common. "
11/01/2014 - "Hypogammaglobulinemia was diagnosed at median of 5.6 months (range: 0-291.8 months) post-transplantation. "

11/20/2019 - "Ongoing study of myotonic dystrophy type 1-associated hypogammaglobulinemia using contemporary tools of genomic medicine may help to further delineate the pathogenesis of this entity."

09/01/1999 - "In the case of agammaglobulinemia effusion and swelling will decrease soon after treatment with intravenous gammaglobulin."
01/01/2021 - "We report the unrelated cases of two young men aged 17 and 22, presenting with persistent hypogammaglobulinemia more than 7 and 10 years after treatment with RTX, respectively, and administered after HSCT for hemolytic anemia and Epstein-Barr virus reactivation, respectively. "
05/01/2008 - "Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma."
01/01/2023 - "Hypogammaglobulinemia (HGG) is a frequent finding in patients with hematological malignancies, and is commonly described in chronic lymphocytic leukemia (CLL) before or after treatment. "
09/27/2021 - "Studying a patient with chronic lymphocytic leukemia and hypogammaglobulinemia who suffered from COVID-19 provided insight in the immunological responses after treatment with COVID-19 convalescent plasma (CCP). "